Warning Letter — Aidance Scientific, Inc.
The FDA issued a Warning Letter to Aidance Scientific, Inc. on October 1, 2026, following an evaluation by the Center for Drug Evaluation and Research (CDER).
This action affects Aidance Scientific, Inc. and specifically impacts regulatory, quality, and marketing functions responsible for drug labeling and compliance.
The issuance of a Warning Letter by CDER typically indicates significant violations of the Federal Food, Drug, and Cosmetic Act, such as the marketing of unapproved new drugs or misbranded products. This suggests a failure in the firm's internal regulatory review processes and potentially requires substantial corrective actions to bring product claims and registrations into compliance.
Regulatory teams should conduct a comprehensive review of all product labeling and marketing materials to ensure claims do not exceed the scope of allowed drug indications. Quality and legal departments should verify that all products marketed as drugs have the necessary FDA approvals or comply with applicable monographs.
FDA Warning Letter issued to: Aidance Scientific, Inc.. 10/01/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/aidance-scientific-inc-735346-10012026
Open in openFDA / FDA.gov